<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We describe a novel double-labeling method to simultaneously investigate proliferation and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> from plastic-embedded biopsy specimens (PEBs) </plain></SENT>
<SENT sid="1" pm="."><plain>Infusions of <z:chebi fb="1" ids="22927,47265">bromo</z:chebi>- and/or iododeoxyuridine (BrdU/IudR) were given to 10 patients, five with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and five with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), and S-phase cells were measured in PEBs using a monoclonal anti-IudR/BrdU antibody </plain></SENT>
<SENT sid="2" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath> was measured by in situ end-labeling (ISEL) of DNA </plain></SENT>
<SENT sid="3" pm="."><plain>The results demonstrate that both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> are highly proliferative disorders but that there is almost no <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in the former, whereas extensive <z:mpath ids='MPATH_3'>apoptosis</z:mpath> was observed in the latter </plain></SENT>
<SENT sid="4" pm="."><plain>Double labeling revealed that large numbers of S-phase cells in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were simultaneously undergoing <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="5" pm="."><plain>We conclude that the high cell <z:hpo ids='HP_0011420'>death</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cancels the high cell birth, resulting in a functionally <z:e sem="disease" ids="C1368107" disease_type="Disease or Syndrome" abbrv="">aplastic marrow</z:e> and thus accounting for the observed ineffective hematopoiesis </plain></SENT>
<SENT sid="6" pm="."><plain>On the other hand, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> is rapidly fatal, probably owing to high cell birth with no or minimal cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Therapeutic strategies to prevent intramedullary programmed cell <z:hpo ids='HP_0011420'>death</z:hpo> of hematopoietic precursors should be evaluated in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, and efficacy of chemotherapy in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> can be assessed by measuring the induction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in post-treatment biopsy specimens </plain></SENT>
</text></document>